Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom

Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom

(1) Aim: To evaluate early real-world outcomes of switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD) in the United Kingdom. (2) Methods: This retrospective, observational study included 59 eyes from 50 patients with treatment-refractory nAMD previously tre...

Full description

Saved in:
Bibliographic Details
Main Authors: Muiz Musadiq, Mohammed Musadiq, Fozia Latif, Benjamin Ng, Matthew Azzopardi, Noa Gilead, Andrew Needham, Yu Jeat Chong
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Life
Subjects:
aflibercept 8 mg
treatment switching
treatment refractory neovascular age-related macular degeneration
Online Access:https://www.mdpi.com/2075-1729/15/6/903
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items